Q-omics provides the consensus-scored MOB1B profile across patient tissues and cancer cell-line models. MOB1B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MOB1B is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, MOB1B RNA expression shows 20,973 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where MOB1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MOB1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MOB1B survival associations across molecular data types. MOB1B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MOB1B RNA expression–survival associations across cancer types. High MOB1B expression shows unfavorable associations in LIHC, LGG, UVM, CESC and ACC, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MOB1B RNA expression.
This table summarizes MOB1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MOB1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MOB1B shows lower tumor expression in KIRC, THCA and KIRP and higher tumor expression in HNSC, CHOL and LIHC. The KIRC box plot shows higher MOB1B RNA expression in normal versus tumor tissue (log2 FC = −1.399, t-test p < 0.001).
This table shows molecular features associated with MOB1B in patient tissues and cancer cell lines. In patient samples, MOB1B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MOB1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
